指南与共识细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

志贺菌控制性人类感染模型免疫学检测共识报告

Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays.
指南 / 共识 · Clin Infect Dis · 2019-01-01

本文报告了2017年两次专家工作组会议关于志贺菌控制性人类感染模型(CHIM)免疫学检测的共识。会议将免疫检测按优先级分为3层,其中抗志贺菌脂多糖(LPS)抗体为最高优先级,并提议建立国际 consortium 与国家生物标准与控制研究所合作建立统一ELISA、生产参考血清及确定LPS可靠来源。

要点

  • 抗志贺菌LPS抗体检测是CHIM免疫学分析的最高优先级。
  • 需建立统一ELISA、参考血清和LPS来源以促进跨研究比较。
  • 共识旨在加速志贺菌疫苗研发、许可和推广。

核心结论

  • 专家共识建议建立国际 consortium 以标准化志贺菌CHIM免疫学检测,优先检测抗LPS抗体。

主要发现

  • 免疫检测被分为3个优先级,抗LPS抗体为最高优先级。
  • 当前CHIM免疫分析因疫苗类型、方案和给药途径而异,检测方法和程序差异限制跨研究比较。

关键数值与推荐

  • 抗志贺菌LPS抗体检测被列为最高优先级(第一层)。
  • 共识建议建立统一ELISA以测定针对志贺菌LPS的血清IgG滴度。

临床怎么用

  • 在志贺菌CHIM研究中优先采用抗LPS抗体检测,并推动使用统一ELISA和参考血清。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Moderate to severe diarrhea caused by Shigella is a global health concern due to its substantial contribution to morbidity and mortality in children aged <5 years in low- and middle-income countries. Although antibiotic treatment can be effective, emerging antimicrobial resistance, limited access, and cost affirm the role of vaccines as the most attractive countermeasure. Controlled human infection models (CHIMs) represent a valuable tool for assessing vaccine efficacy and potentially accelerating licensure. Currently, immunological analysis during CHIM studies is customized based on vaccine type, regimen, and administration route. Additionally, differences in type of immunoassays and procedures used limit comparisons across studies. In November 2017, an expert working group reviewed Shigella CHIM studies performed to date and developed consensus guidelines on prioritization of immunoassays, specimens, and collection time points. Immunoassays were ranked into 3 tiers, with antibodies to Shigella lipopolysaccharide (LPS) being the highest priority. To facilitate comparisons across clinical studies, a second workshop was conducted in December 2017, which focused on the pathway toward a recognized enzyme-linked immunosorbent assay (ELISA) to determine serum immunoglobulin G titers against Shigella LPS. The consensus of the meeting was to establish a consortium of international institutions with expertise in Shigella immunology that would work with the National Institute for Biological Standards and Control to establish a harmonized ELISA, produce a reference sera, and identify a reliable source of Shigella LPS for global utilization. Herein we describe efforts toward establishing common procedures to advance Shigella vaccine development, support licensure, and ultimately facilitate vaccine deployment and uptake.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kaminski RW, Pasetti MF, Aguilar AO, et al. Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays. Clin Infect Dis. 2019. PMID: 31816067. doi:10.1093/cid/ciz909

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。